Form 4: Ligand Pharmaceuticals Director Sells Shares
Statement of Changes in Beneficial Ownership
Ligand Pharmaceuticals Director John W. Kozarich reported the sale of common stock valued at over $100,000 through a pre-arranged trading plan.
Summary
- Director John W. Kozarich of Ligand Pharmaceuticals Inc. (LGND) reported transactions involving the sale of common stock.
- These sales occurred on April 1, 2026, and were executed under a written trading plan adopted on March 7, 2025, in accordance with Rule 10b5-1.
- A total of 420 shares were sold across multiple transactions at weighted-average prices ranging from $199.69 to $204.54.
- Following these transactions, Kozarich beneficially owns 42,253 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it reports routine insider stock sales conducted under a pre-arranged trading plan, which is a common and expected corporate disclosure.
Negatives
- Director John W. Kozarich sold a total of 420 shares of Ligand Pharmaceuticals Inc. common stock.
- The total value of the shares sold is approximately $85,000 based on the weighted average prices reported.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing, which solely reports past transactions.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency to the market regarding the buying and selling activities of company directors and officers. The use of a Rule 10b5-1 plan indicates a structured approach to these transactions, often implemented to avoid concerns about insider trading.
Stakeholder Impact
- Shareholders: The sale of shares by a director may be interpreted by some shareholders as a signal, though the use of a 10b5-1 plan mitigates concerns about non-public information.
- Management: Demonstrates adherence to disclosure requirements and structured trading practices.
Key Dates
| Date | Description |
|---|---|
| 03/07/2025 | Date the written trading plan was adopted by the Reporting Person in accordance with Rule 10b5-1. |
| 04/01/2026 | Date of earliest transaction reported and date of stock sales. |
| 04/02/2026 | Date the Form 4 was signed by the attorney-in-fact for the Reporting Person. |
Keywords
Form 4, SEC Filing, Insider Trading, Stock Sale, Ligand Pharmaceuticals, LGND, Director Transaction, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.